Hough Ear Institute (HEI) is fully supporting our commercialization partner, Otologic Pharmaceutics, Inc. (OPI), as they work to advance NHPN-1010 through the FDA approval process. However, many of the key approval steps are beyond HEI’s control. HEI and the Oklahoma Medical Research Foundation (OMRF) developed NHPN-1010 for hearing loss, and HEI funded much of its pre-clinical research. Now, a pharmaceutical partner is needed to fund the remaining clinical trials through Phases II and III, a process requiring an investment of nearly $500 million.

OPI secured a pharmaceutical partner for Phase II testing in 2020, but that company shifted focus to cancer research, returning the license to OPI. OPI is now working to find another partner to continue development. HEI has no control over this process, which can take years and is confidential until an agreement is finalized. Once a new partner is secured, they will control NHPN-1010’s clinical development.

We understand how important this is for those affected by hearing loss and tinnitus, and we are committed to continuing this journey toward FDA approval. We will keep you informed as progress is made.

For updates on the status of NHPN-1010's clinical development, please contact Elaine Hamm at ehamm@ascendbioventures.com. If you would like additional information from Hough Ear Institute, please reach out to info@houghear.org.